Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Accessibility Statement] Skip NavigationGAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register ...

Company Performance - Novavax (NVAX) closed at $8.97, reflecting a +2.51% increase from the previous day, outperforming the S&P 500 which had a daily loss of 0.01% [1] - Over the past month, Novavax shares gained 0.92%, while the Medical sector and S&P 500 experienced losses of 1.31% and 0.28% respectively [1] Earnings Expectations - The upcoming earnings report for Novavax is expected to show an EPS of -$0.66, a decline of 29.41% compared to the same quarter last year [2] - Revenue is anticipated to be $78.41 million, indicating an 11.21% decrease from the same quarter of the previous year [2] Full-Year Estimates - Zacks Consensus Estimates project full-year earnings of $1.94 per share and revenue of $1.05 billion, representing year-over-year increases of +257.72% and +54.62% respectively [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for Novavax are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that 1 ranked stocks have yielded an average annual return of +25% since 1988 [6] - Novavax currently holds a Zacks Rank of 3 (Hold), with a 9.04% increase in the Zacks Consensus EPS estimate over the last 30 days [6] Industry Context - Novavax operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [7]

Group 1 - Pfizer Inc. is set to release its fourth-quarter earnings results on February 3, with analysts expecting earnings of 57 cents per share, a decrease from 63 cents per share in the same period last year [1] - The consensus estimate for Pfizer's quarterly revenue is $16.83 billion, down from $17.76 billion a year earlier [1] Group 2 - Novavax, Inc. announced a license agreement with Pfizer for the use of its Matrix-M adjuvant on January 20 [2] - Following the announcement, Pfizer's shares increased by 1.4%, closing at $26.44 [2]

Core Insights - Moderna, Inc. (MRNA) and Novavax, Inc. (NVAX) were highly discussed stocks in the biotech, pharma, and healthcare sectors five years ago, indicating their significant market presence and investor interest [1]. Group 1 - The investing group Haggerston BioHealth, led by a biotech consultant with over five years of experience, provides detailed reports on more than 1,000 companies in the biotech, healthcare, and pharma industries [1]. - Haggerston BioHealth offers insights into catalysts for investment decisions, including buy and sell ratings, product sales forecasts, and integrated financial statements [1]. - The group also conducts discounted cash flow analysis and market-by-market analysis for major pharmaceutical companies [1].

Group 1 - Pfizer Inc. is considered one of the best inexpensive stocks to buy currently, particularly following a licensing agreement with Novavax for the Matrix-M adjuvant technology [1] - The Matrix-M technology is intended to enhance immune responses to vaccines and will be utilized by Pfizer for two infectious diseases, with Pfizer managing development, manufacturing, and commercialization [1] - Pfizer announced positive results from the BREAKWATER trial, showing a 64% objective response rate for the BRAFTOVI regimen combined with cetuximab and FOLFIRI in patients with metastatic colorectal cancer, compared to 39% for standard treatment [2][3] Group 2 - The addition of chemotherapy to the BRAFTOVI regimen significantly improved response rates, indicating potential flexibility in treatment options for patients with BRAF V600E mutations [3] - Pfizer's operations encompass the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products both in the US and internationally [4]

Core Insights - Novavax (NVAX) has entered a non-exclusive license agreement with Pfizer (PFE), allowing Pfizer to utilize its Matrix-M adjuvant technology for up to two disease areas, indicating the growing recognition of Matrix-M's versatility in vaccine development [1] Financial Highlights - Novavax will receive an upfront payment of $30 million from Pfizer and has the potential to earn up to $500 million in development and commercial milestone payments, along with tiered, high, mid-single-digit royalties on net sales of products incorporating Matrix-M [2][6] - Over the past year, NVAX's shares have decreased by 7.1%, while the industry has seen a rise of 15.1% [3] Matrix-M Adjuvant Technology - Matrix-M is a proprietary, saponin-based adjuvant technology from Novavax designed to enhance immune responses to vaccines, currently used in a globally approved vaccine and as a key component of Novavax's COVID-19 vaccine, Nuvaxovid/Covovax [4] - The University of Oxford has utilized Matrix-M to develop the R21 malaria vaccine, with commercialization rights licensed to the Serum Institute of India, and several other partners are evaluating Matrix-M for malaria vaccine development [7] Licensing Agreements - Novavax has a co-exclusive licensing agreement with Sanofi (SNY) that includes a non-exclusive license for Matrix-M in vaccine products, with the agreement amended in September 2025 to expand Sanofi's license for its pandemic influenza vaccine candidate program, potentially earning Novavax up to $210 million plus mid-single-digit royalties [8] - In 2023, Matrix-M technology was also licensed to the Bill & Melinda Gates Medical Research Institute and SK Bioscience for preclinical vaccine research, supporting global vaccine discovery efforts [9]

Core Insights - The licensing deal for Novavax, Inc. (NVAX) is significant as it validates the commercial and scientific value of their Matrix-M adjuvant beyond their own vaccine portfolio [1] Company Overview - Novavax is focusing on innovative biotechnology solutions, particularly through unique mechanisms of action and first-in-class therapies [1] - The company aims to reshape treatment paradigms with its platform technologies [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis [1] - The analyst has been active in the investing space for five years, with a focus on biotech equity analysis [1] Research Focus - The research emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and market opportunities [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector [1]

Core Viewpoint - Novavax Inc. has signed a licensing agreement with Pfizer for its Matrix-M adjuvant, valued at up to $500 million, which includes a $30 million upfront payment [1] Group 1: Stock Performance - Novavax shares have increased by 3.3%, trading at $8.27, and have risen 65% from a low of $5.01 on April 10 [1][2] - The stock reached its highest level since October after bouncing off support at the $6.50 level, indicating a potential upward trend [2] - If the current gains are maintained, it will mark the third gain in the last five trading sessions [2] Group 2: Analyst Ratings - The analyst community is divided, with five analysts rating Novavax as a "strong buy" while another five suggest a "hold" or worse [2] - Short interest in Novavax accounts for 36.9% of the available float, indicating a significant level of bearish sentiment among investors [2] Group 3: Options Trading Activity - Options traders have shown strong bullish sentiment, as evidenced by a 50-day call/put volume ratio of 29.67, the highest in the past year [3] - Novavax's Schaeffer's Volatility Index (SVI) stands at 57%, which is higher than only 18% of readings from the past year, suggesting that near-term options traders expect relatively low volatility [3]

Core Viewpoint - Novavax has entered into a license agreement with Pfizer for the use of its Matrix-M adjuvant, allowing Pfizer to utilize this technology in the development of products for up to two disease areas [1][4]. Group 1: License Agreement Details - The agreement grants Pfizer a non-exclusive license for Matrix-M, which is expected to enhance Pfizer's product development capabilities [1][4]. - Novavax will receive an upfront payment of $30 million and has the potential to earn up to $500 million in development and sales milestones [4][5]. - In addition to milestone payments, Novavax is eligible for tiered high mid-single digit percentage royalties on sales of any Pfizer product that incorporates Matrix-M [5]. Group 2: Responsibilities and Future Prospects - Pfizer will be solely responsible for the development and commercialization of its products utilizing Matrix-M, while Novavax will supply the Matrix-M adjuvant [5]. - The agreement is part of Novavax's broader strategy to optimize existing partnerships and expand its technology platform through research and development innovation [2].

Group 1 - Novavax is entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases [1]